Jubilant Pharmova Ltd.
NSE: JUBLPHARMA | BSE: 530019
₹1,011.65
₹-2.55
(-0.25%)
As on 21-May-2026IST
Market cap
₹16,107 Cr
Revenue (TTM)
₹7,918 Cr
P/E Ratio
37.2
P/B Ratio
2.4
Div. Yield
0.5 %
Quality Score
3/10
Growth Score
6/10
Valuation Score
3/10
Momentum Score
4/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹433 Cr
-
ROE
14.3 %
-
ROCE
13.9 %
-
Industry P/E
44.31
-
EV/EBITDA
13.7
-
Debt to Equity
0.4
-
Book Value
₹417.3
-
EPS
₹29
-
Face value
1
-
Shares outstanding
159,281,139
10 Years Aggregate
CFO
₹11,660.93 Cr
EBITDA
₹12,801.07 Cr
Net Profit
₹4,681.62 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| -5.7 | 11.7 | 15.9 | 2.3 | 42.9 | 3.6 | 19.6 |
|
BSE Healthcare
| 10.2 | 10.3 | 11.1 | 13.4 | 28.1 | 14.5 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| -0.6 | 90.5 | 45.6 | -36.1 | -31.1 | 58.6 | -24.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
|
1,011.7 | 16,107.3 | 7,918.4 | 429.9 | 10.7 | 7.2 | 37.2 | 2.4 |
| 3,000.4 | 24,554.0 | 1,339.4 | 356.4 | 33.2 | 23.2 | 68.9 | 14.8 | |
| 748.9 | 14,696.0 | 7,344.9 | 670.6 | 10.9 | 13.7 | 21.8 | 2.6 | |
| 419.9 | 16,087.0 | 2,268.6 | 150.1 | 10.6 | 5.4 | 89.8 | 4.1 | |
| 764.2 | 18,926.7 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.8 | 3.7 | |
| 1,174.3 | 21,003.3 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.5 | 2.4 | |
| 1,861.8 | 21,346.5 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.7 | |
| 176.1 | 23,381.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.9 | |
| 470.2 | 18,982.5 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.9 | 3.9 | |
| 1,599.8 | 26,016.6 | 3,373.0 | 199.0 | 12.6 | 5.9 | 122.1 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
About Jubilant Pharmova
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables,... Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India. Read more
-
Incorporated
1978
-
Chairman
Shyam S Bhartia
-
Managing Director
Priyavrat Bhartia
-
Group
Jubilant Bhartia
-
Headquarters
Gajraula, Uttar Pradesh
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsSubmission Of Communication Sent To Shareholders
30-Mar-2026No News & Announcements are available.
FAQs for Jubilant Pharmova
What is the current share price of Jubilant Pharmova Ltd Today?
The share price of Jubilant Pharmova Ltd is ₹1,011.65 (NSE) and ₹1,011.25 (BSE) as of 21-May-2026 IST. Jubilant Pharmova Ltd has given a return of 42.95% in the last 3 years.
What is the current PB & PE ratio of Jubilant Pharmova Ltd?
The P/E ratio of Jubilant Pharmova Ltd is 37.23 times as on 21-May-2026, a 16 discount to its peers’ median range of 44.31 times.
The P/B ratio of Jubilant Pharmova Ltd is 2.42 times as on 21-May-2026, a 38 discount to its peers’ median range of 3.89 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.80
|
2.26
|
|
2024
|
116.50
|
1.66
|
|
2023
|
0.00
|
0.82
|
|
2022
|
14.91
|
1.16
|
|
2021
|
12.96
|
2.28
|
What is the 52 Week High and Low of Jubilant Pharmova Ltd?
The 52-week high and low of Jubilant Pharmova Ltd are Rs 1,248.00 and Rs 786.05 as of 21-May-2026.
What is the market cap of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a market capitalisation of ₹ 16,107 Cr as on 21-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Jubilant Pharmova Ltd?
Before investing in Jubilant Pharmova Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.